TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02163759
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
Study: NCT03417388
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be recommended to IMT women without contraindications or bleeding risk.
Study: NCT02163759
Drug: Etrolizumab
Normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Study: NCT00093626
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00588016
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
Study: NCT06286488
Drug: Vaxigrip
DrugBank: Haemagglutinin-strain A(H3N2) (DB15475)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
Study: NCT00333437
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03556254
Drug: GGT
Normalized name: NGGT-002
DrugBank: NGGT-002 (DB17881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
Study: NCT03556254
Drug: SGT
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
Study: NCT03022526
Drug: Bupivacaine / fentaNYL
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003523
Drug: aminocamptothecin colloidal dispersion
Normalized name: amphotericin B colloidal dispersion
DrugBank: Camptothecin (DB04690)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05199103
Drug: rabbit anti-thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
Study: NCT04721886
Drug: Perflutren Lipid Microcpheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03566134
Drug: DA-8010 5mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive DA-8010 5mg orally once a day.
Study: NCT03566134
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive solifenacin 5 mg orally once a day.
Study: NCT03566134
Drug: Solifenacin succinate placebo
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.
Study: NCT04198558
Drug: MEDI0618
DrugBank: MEDI0680 (DB15768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0618 A novel human immunoglobulin antibody
Study: NCT03891108
Drug: BMS-986231 Formulation A
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
Study: NCT03891108
Drug: BMS-986231 Formulation C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
Study: NCT02442739
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
Study: NCT01397214
Drug: Megace OS
Normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megace oral suspension
Study: NCT05035381
Drug: Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
Study: NCT02037399
Drug: intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Study: NCT00380575
Drug: YM087
Normalized name: Nepadutant
DrugBank: Nepadutant (DB12538)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02037399
Drug: intravenous normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Study: NCT03311243
Drug: Chemical plaque control
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01860066
Drug: fluticasone/salmeterol
Normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fluticasone/salmeterol via inhaler twice a day
Study: NCT02849899
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.
Study: NCT00066859
Drug: Zoloft 50 mg
Normalized name: Zoloft 50 MG Oral Tablet
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
Study: NCT03903406
Drug: ixazomib in combination with lenalidomide and dexamethasone
Normalized name: dexamethasone, combinations
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
Study: NCT04109261
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
Study: NCT04575233
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
Study: NCT00811018
Drug: Sitaxsentan
Normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sitaxsentan 100 mg tablets once daily
Study: NCT01170169
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole Delayed Release Capsules 40 mg
Study: NCT01170169
Drug: Prilosec
Normalized name: Prilosec
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilosec® 40 mg of Merck \& Co.Inc.
Study: NCT02094924
Drug: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of FDC tablet formulation to be taken orally
Study: NCT00988728
Drug: SCH 900435 (Org 25935)
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day).
Study: NCT00988728
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day).
Study: NCT02403648
Drug: Lilly Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02403648
Drug: Novo Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03941288
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued.
Study: NCT00334048
Drug: Ropinirole (Requip)
Normalized name: ropinirole Extended Release Oral Tablet [Requip]
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg extended release formulation given once per day to a maximum of 4 per day
Study: NCT00929695
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunosuppressive drug
Study: NCT00929695
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: immunosuppressive drug
Study: NCT03950297
Drug: 609A
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
Study: NCT03224819
Drug: Emerfetamab
Normalized name: Emerfetamab
DrugBank: Emerfetamab (DB18474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion.
Study: NCT02131753
Drug: Cladribine s.c. injection, HCL treatment
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
Study: NCT02015312
Drug: Epigallocatechin-3-gallate (EGCG)
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Study: NCT02546388
Drug: Indium-111 Pentreotide
Normalized name: Indium-111 Pentetreotide
DrugBank: Indium (DB11659)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546388
Drug: Gallium-68 DOTATATE
Normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00209612
Drug: Taxol
Normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day1,15 X mg/m2, IV (in the vein)
Study: NCT02129699
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
Study: NCT03410693
Drug: Rogaratinib (BAY1163877)
Normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
Study: NCT01881828
Drug: Metformin (glucophage)
Normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
Study: NCT00928408
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06365424
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate (200 mg/day)
Study: NCT06365424
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13-15 mg/kg/day)
Study: NCT00689858
Drug: Cilostazol, Ginkgo biloba and placebo
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosing time
Study: NCT03405194
Drug: Elvitegravir, Cobicistat, TAF, FTC
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Started on day of HIV diagnosis
Study: NCT03405194
Drug: Efavirenz, TDF, and 3TC
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Started on day of HIV diagnosis
Study: NCT00067431
Drug: Divalproex Sodium (Depakote® Sprinkle Capsules)
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00540982
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mg/kg will be administered by IV push to determine clearance
Study: NCT00540982
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg will be administered to determine metabolic capacity
Study: NCT00540982
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
Study: NCT04328077
Drug: TERN-101
Normalized name: TERN-101
DrugBank: TERN-101 (DB16045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT01081431
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg d1-d21 of a 28-day cycle
Study: NCT00953576
Drug: ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00953576
Drug: dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00953576
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00403962
Drug: vestipitant/paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00915382
Drug: S-1 and cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1
Study: NCT00915382
Drug: S-1 and cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8
Study: NCT01340846
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin dosed at 15mg on Day 1 and Day 22
Study: NCT01340846
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole dosed at 400mg daily on Days 19 through 22
Study: NCT01340846
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
Study: NCT03714958
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT04398927
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab
Study: NCT04122716
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics.
Study: NCT00045760
Drug: Drotrecogin alfa (activated)
Normalized name: DROTRECOGIN ALFA (ACTIVATED)
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446574
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: starting dose 20mg/m2 qw
Study: NCT02446574
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose 25mg/m2 qw
Study: NCT00887562
Drug: Idebenone
Normalized name: Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 900 mg/day for 1 month
Study: NCT00887562
Drug: Idebenone
Normalized name: Idebenone
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 2250 mg/day for 1 month
Study: NCT03367676
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
Study: NCT03367676
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100mg/m2，d1，iv，q3w\*4
Study: NCT01516060
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg qd; 2 x 200mg
Study: NCT01516060
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg qd; 3 x 200mg qd
Study: NCT01610934
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.